This blog is written by Mr. Steven C. Schurr, Esq. and focuses on health care law matters that pertain to food and drug law, regulatory compliance, privacy rights, insurance coverage, state and federal disability coverage, patient advocacy issues, and mental health coverage and treatment.

Wednesday, February 15, 2017

Senators Propose Importation of Less Expensive Pharmaceuticals from Canada If US Prices Rise

Several Senators call for the allowance of importation of expensive medications from Canada under certain circumstances.  This has been expressed in a letter to the new Secretary of Health and Human Services, Tom Price.  Attached is the letter from Senators Chuck Grassley (R-IA), John McCain (R-AZ) and Amy Klobuchar (D-MN):
"Those circumstances are: If a drug is off patent or no longer marketed in the US by the innovator company that initially developed that drug; if there are “significant and unexplained increases in price”; if no direct competitor drug is currently marketed and the introduction of such a competitor will lower prices for taxpayers and consumers; or if the drug is produced in another country by a brand name manufacturer or by a “well-known generic manufacturer that commonly sells pharmaceutical products in the US.”  - Zachary Brennan, Regulatory Affairs Professionals Society
The unknown receipt of counterfeit drugs from illegitimate destinations can be a problem if ordered from a Canadian Pharmacy but this can be avoided by proper screening and vetting of the approved pharmacies.  I am in favor of this policy if it can be implemented properly.
See the attached newsletter from the Regulatory Affairs Professionals Society (RAPs):

No comments: